E
Ed Parsley
Researcher at University of Texas Health Science Center at Houston
Publications - 5
Citations - 1942
Ed Parsley is an academic researcher from University of Texas Health Science Center at Houston. The author has contributed to research in topics: Interstitial lung disease & FEV1/FVC ratio. The author has an hindex of 4, co-authored 4 publications receiving 1780 citations. Previous affiliations of Ed Parsley include University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Cyclophosphamide versus placebo in scleroderma lung disease.
Donald P. Tashkin,Robert Elashoff,Philip J. Clements,Jonathan G. Goldin,Michael D. Roth,Daniel E. Furst,Edgar Arriola,Richard M. Silver,Charlie Strange,Marcy B. Bolster,James R. Seibold,David J. Riley,Vivien Hsu,John Varga,Dean E. Schraufnagel,Arthur C. Theodore,Robert W. Simms,Robert A. Wise,Fredrick M. Wigley,Barbara White,Virginia D. Steen,Charles A. Read,Maureen D. Mayes,Ed Parsley,Kamal K. Mubarak,M. Kari Connolly,Jeffrey A. Golden,Mitchell A. Olman,B. J. Fessler,Naomi F. Rothfield,Mark L. Metersky +30 more
TL;DR: One year of oral cyclophosphamide in patients with symptomatic scleroderma-related interstitial lung disease had a significant but modest beneficial effect on lung function, dyspnea, thickening of the skin, and the health-related quality of life.
Journal ArticleDOI
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.
Donald P. Tashkin,Robert Elashoff,Philip J. Clements,Michael D. Roth,Daniel E. Furst,Richard M. Silver,Jonathan G. Goldin,Edgar Arriola,Charlie Strange,Marcy B. Bolster,James R. Seibold,David J. Riley,Vivien Hsu,John Varga,Dean E. Schraufnagel,Arthur C. Theodore,Robert W. Simms,Robert A. Wise,Fred M. Wigley,Barbara White,Virginia D. Steen,Charles A. Read,Maureen D. Mayes,Ed Parsley,Kamal K. Mubarak,M. Kari Connolly,Jeffrey A. Golden,Mitchell A. Olman,Barri J. Fessler,Naomi F. Rothfield,Mark L. Metersky,Dinesh Khanna,Ning Li,Gang Li +33 more
TL;DR: One year of CYC improved lung function, skin scores, dyspnea, and health status/disability, effects which either persisted or increased further for several months after stopping therapy, but all of these effects waned and were no longer apparent at 24 months.
Journal ArticleDOI
Bronchoalveolar Lavage and Response to Cyclophosphamide in Scleroderma Interstitial Lung Disease
Charlie Strange,Marcy B. Bolster,Michael D. Roth,Richard M. Silver,Arthur C. Theodore,Jonathan G. Goldin,Philip J. Clements,Joanie Chung,Robert Elashoff,Robert D. Suh,Edwin A. Smith,Daniel E. Furst,Donald P. Tashkin,Philip J. Clements,Robert E. Elashoff,Michael Roth,Daniel Furst,Ken Bulpitt,Dinesh Khanna,Wen Ling Joanie Chung,Sherrie Viasco,Mildred Sterz,Lovlette Woolcock,Xiaohong Yan,Judy Ho,Sarinnapha Vasunilashorn,Irene Da Costa,James R. Seibold,David J. Riley,Judith K. Amorosa,Vivien Hsu,Deborah A. McCloskey,Julianne E. Wilson,John Varga,Dean Schraufnagel,Andrew Wilbur,David Lapota,Shiva Arami,Patricia Cole-Saffold,Robert W. Simms,Peter Clarke,J H Korn,Kimberley Tobin,Melynn Nuite,Richard I. Silver,Marcie Bolster,Steve Schabel,Edwin Smith,June Arnold,Katie Caldwell,Michael F. Bonner,Robert A. Wise,Fred M. Wigley,Barbara White,Laura K. Hummers,Mark Bohlman,Albert J. Polito,Gwen Leatherman,Edrick Forbes,Marie Daniel,Virginia D. Steen,Charles A. Read,Cirrelda Cooper,Sean Wheaton,Anise Carey,Adriana Ortiz,Maureen Mayes,Ed Parsley,Sandra A. A. Oldham,Tan Filemon,Samantha Jordan,Marilyn Perry,Kari Connolly,Jeffrey Golden,Paul Wolters,Richard Webb,John A. Davis,Christine Antolos,Carla Maynetto,Naomi F. Rothfield,Mark Metersky,Richard Cobb,Macha Aberles,Fran Ingenito,Elena Breen,Kamal K. Mubarak,José L. Granda,Joseph Silva,Zora Injic,Ronika Alexander,Steven Springmeyer,Steven Kirkland,Jerry A. Molitor,Richard Hinke,Amanda Mondt,Mitchell A. Olman,Barri J. Fessler,Colleen Sanders,Louis W. Heck,Tina Parkhill +99 more
TL;DR: The presence of an abnormal lavage in the Scleroderma Lung Study defined patients with more advanced interstitial lung disease but added no additional value to physiologic and computed tomography findings as a predictor of progression or treatment response.
Journal ArticleDOI
Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study.
Dinesh Khanna,Xiaohong Yan,Donald P. Tashkin,Daniel E. Furst,Robert Elashoff,Michael D. Roth,Richard M. Silver,Charlie Strange,Marcy B. Bolster,James R. Seibold,David J. Riley,Vivien Hsu,John Varga,Dean E. Schraufnagel,Arthur C. Theodore,Robert W. Simms,Robert A. Wise,Fredrick M. Wigley,Barbara White,Virginia D. Steen,Charles A. Read,Maureen D. Mayes,Ed Parsley,Kamal K. Mubarak,M. Kari Connolly,Jeffrey A. Golden,Mitchell A. Olman,B. J. Fessler,Naomi F. Rothfield,Mark L. Metersky,Philip J. Clements +30 more
TL;DR: One year of treatment with CYC leads to an improvement in HRQOL in patients with scleroderma lung disease, and differences in the HAQ DI,SF-36 role physical, general health, vitality, role emotional, mental health scales, and SF-36 mental component summary (MCS) score were statistically significant for CYC versus placebo.